Effects of desferrioxamine on human cytomegalovirus replication and expression of HLA antigens and adhesion molecules in human vascular endothelial cells

Transplant Immunology

Volumn 3, Issue 4, 1995, Pages 313-320

  Cinatl, Jindrich ^a   Scholz, Martin ^a   Weber, Bernard ^a   Cinatl, Jaroslav ^a   Rabenau, Holger ^a   Markus, Bernd H ^a   Encke, Albrecht ^a   Doerr, Hans Wilhelm ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HLA ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; GRAFT REJECTION; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM; VIRUS REPLICATION;

EID: 0029558928     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/0966-3274(95)80017-4     Document Type: Article

References (51)

1. Epidemiology of cytomegalovirus infection after transplantation and immunosuppression
2. Congenital and perinatal cytomegalovirus infections
3. Herpesvirus infections in the acquired immune deficiency syndrome
4. Cytomegalovirus. The troll of transplantation
5. Cytomegalovirus infection and cytomegalic inclusion disease in renal homotransplant recipients
6. Impact of cytomegalovirus infection on organ transplant recipients
7. The antimicrobial activities of cyclosporine, FK506, and rapamycin
8. Infections under FK506 immunosuppression: preliminary results with primary therapy
9. Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects
10. Long term chelation therapy in thalassemia major: effect on liver iron concentration, liver histology and clinical progress
11. The management of iron chelation therapy
12. Iron-chelating agents in non-iron overload conditions
13. Desferrioxamine (DFO) inhibition of interleukin 2 receptor (IL2R) expression: therapy of graft versus host disease (GVHD)
14. Desferrioxamine blocks IL 2 receptor expression on human T lymphocytes
15. Mechanism of inhibition of mononuclear cell activation by the iron-chelating agent desferrioxamine
16. In vitro inhibition of human cytomegalovirus replication by desferrioxamine
17. Induction of endothelial cell procoagulant activity by cytomegalovirus infection
18. Vascular endothelium in immunology and infectious disease
19. Lymphocyte interactions with endothelial cells
20. Adhesion molecules and inflammatory injury
21. Mechanisms of T cell recognition of alloantigen
22. Culture of endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria
23. Rapid (24h) neutralization assay for the detection of antibodies to human cytomegalovirus using a monoclonal antibody to an HCMV early nuclear protein
24. Cytomegalovirus- and interferon-related effects on human endothelial cells: cytomegalovirus infection reduces upregulation of HLA class II antigen expression after treatment with interferon-gamma
25. Adhesion and penetration properties of human lymphocytes acting on allogeneic vascular endothelial cells
26. Pathology of human cytomegalovirus infection
27. The risk of cytomegalovirus infection in solid organ and bone marrow transplant recipients: transfusion of blood products
28. Cytomegalovirus infection after solid organ transplantation
29. Cytomegalovirus in bone marrow transplantation
30. The management of cytomegalovirus infection in heart-lung transplant recipients
31. Metabolic activation of the nucleoside analog 9-(1,3-dihydroxy-2-propoxymethyl)guanine in human diploid fibroblasts infected with human cytomegalovirus
32. Effect of iron deficiency and desferrioxamine on DNA synthesis in human cells
33. Models of the regulation of ribonucleotide reductase and their evaluation in intact mammalian cells
34. Impairment of nucleotide metabolism by iron chelating deferoxamine
35. Inhibition of glutathionsynthetase leads to enhanced expression of cytomegalovirus-specific proteins in human endothelial cells
36. Antiviral effect of L-ascorbic acid 2-phosphate on the replication of human cytomegalovirus in cultured fibroblasts
37. Inhibition of autoimmune neuropathological process by treatment with an iron-chelating agent
38. Desferrioxamine treatment prevents chronic islet allograft damage
39. Iron and deferoxamine in lymphocyte blastogenesis
40. The effect of desferrioxamine on the proliferative response of rat lymphocyte stimulated with various mitogens in vitro
41. Inflammation-induced endothelial cell adhesion to lymphocytes, neutrophils, and monocytes
42. Lymphocyte migration patterns in organ allograft recipients
43. Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1
44. A single administration of LFA-1 antibody confers prolonged allograft survival
45. Potent and effective prolongation by anti-LFA-1 monoclonal antibody monotherapy of non-primarily vascularized heart allograft survival in mice without T cell depletion
46. Prolongation of murine cardiac allograft survival with monoclonal antibodies to LFA-1, ICAM-1 and CD-4
47. Prolongation of human pancreatic islet xenografts by pretreatment of islets with anti-human ICAM-1 monoclonal antibody
48. Retinoic acid inhibits expression of E-selectin in endothelial cells and prolongs discordant xenograft survival
49. A phase I trial of immunosuppression with anti-ICAM-1 (CD54) mAb in renal allograft recipients
50. Cytomegalovirus-infected human endothelial cells express increased levels of ICAM-1
51. Contribution of ICAM-1 to the activation of CD4+ T cells by CMV-infected, allogeneic human endothelial cells